Journal of Preventive Medicine & Public Health

General Information

The mission of the Journal of Preventive Medicine and Public Health (JPMPH) is to promote research, policy, education, and practice in the field of preventive medicine and public health by publishing papers of high scientific quality. Contributions of original articles, reviews, special articles, brief reports, perspectives and critical commentaries, letters, methods in the fields of research, and public health debates are welcome. The journal is issued six times a year (the last day of January, March, May, July, September, and November) and the contents of the JPMPH are indexed in MEDLINE, Emerging Sources Citation Index (ESCI), PubMed, PubMed Central, KoreaMed, KoMCI, CrossRef, Scopus, EMBASE, EBSCO, CAS, DOAJ, and Google Scholar.

Editorial and Publication Policies

Research and Publication Ethics

For the policies on research and publication ethics not stated in the Instructions, Guidelines on Good Publication (http://publicatioethics.org/) or Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/) can be applied.

Authorship

Authorship credit should be based on: (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged as contributors not be authors.

The addition of an author to a manuscript under review is possible only with the editor’s approval. Changes in authorship cannot be made after the manuscript is accepted for publication.

Corresponding author and first author: When a study is conducted by a large and multicenter group, the group should identify the individual authors who accept responsibility for the manuscript before submission. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as group name. JPMPH does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.

Originality, Plagiarism and Duplicate Publication

Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by CrossCheck (http://www.ithenticate.com/) upon arrival. If plagiarism or duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors.

A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.

Secondary Publication

It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the International Committee of Medical Journal Editors (ICMJE) Recommendations (http://www.icmje.org/urm_main.html).

Conflict of Interest Statement

The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, po-
itical pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.

**Statement of Human and Animal Right**

Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Subjects, outlined in the Helsinki Declaration (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. Human subjects should not be identifiable, such that patients’ names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.

**Description of Participants**

Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.

**Statement of Informed Consent and Institutional Review Board Approval**

Copies of written informed consent documents should be kept for studies on human subjects. For clinical studies of human subjects, a certificate, agreement, or approval by the institutional review board (IRB) of the author’s institution is required. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.

Process for Managing Research and Publication Misconduct

When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.

**Editorial Responsibilities**

The Editorial Board will continuously work to monitor and safeguard publication ethics: guidelines for retracting articles; maintenance of the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and excluding plagiarism and fraudulent data. The editors maintain the following responsibilities: responsibility and authority to reject and accept articles; avoiding any conflict of interest with respect to articles they reject or accept; promoting publication of corrections or retractions when errors are found; and preservation of the anonymity of reviewers.

**Reviewer Responsibilities**

The peer reviewers are prohibited from copying manuscripts, sharing with others, and discussing their personal evaluations or recommendations. The peer reviewers are also asked to report immediately any possible conflicts of interest with authors or related to a paper’s topic and to destroy manuscript copy upon completion of review.

**Registration of Clinical Trial Research**

It is recommended that any research dealing with a clinical trial be registered at an appropriate online public registry. Manuscript with non-registered interventional clinical trials will not be considered for publication.

**Data Sharing Statement**

JPMPH accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines.

**Manuscript of Categories**

**Original Articles**

Manuscripts that report the results of original quantitative or qualitative public health research are published as original articles. This includes reports of randomized controlled trials (RCTs), observational studies, and other basic clinical and public health
reviews. An original article includes a structured abstract of 250 words or fewer, up to 3000 words in the main text (not including abstract, tables, figures, references, and online-only material), with up to 5 tables and figures and no more than 40 references. The main text must follow the standard JPMPH format, with an Introduction and separate sections for Methods, Results, and Discussion. Acknowledgments and further disclosures (i.e., conflict of interest, data availability statement and, if applicable ethics statement, disclaimer, funding, etc.), References, Figure legends, and Tables follow the body of the text. Original Articles should also include a brief description (maximum 100 words) of the “Key Summary” of the work on the title page of the paper. This format is the highest priority for the JPMPH and represents the majority of papers published. All submissions must follow the appropriate reporting guidelines.

JPMPH requires authors of manuscripts pertaining to clinical trials to register their study in an ICMJE-approved registry. Registration must be completed before any enrollment.

Reviews

Reviews are invited by the editor and should be comprehensive analyses of specific topics. They are to be organized as follows: title page, abstract and keywords, main text (introduction, text, and conclusion), conflict interest, acknowledgments, references, tables, figure legends, and figures. There should be an unstructured abstract of no more than 250 words. The text should not exceed 5000 words in length (not including abstract, tables, figures, references, and online-only material), with up to 100 references and no more than a total of 6 tables and figures.

Systematic Review (including Meta-analysis)

These articles present a comprehensive search and appraisal of accumulating evidence of an important public health topic using a systematic approach. A systematic review may, or may not, include a meta-analysis. A structured abstract of 250 words is required; for more information, see instructions for preparing structured abstracts. The text should not exceed 3500 words in length (not including abstract, tables, figures, references, and online-only material), with up to 100 references and no more than a total of 6 tables and figures. The main text of the systematic review must follow the standard JPMPH original article format, with an Introduction and separate sections for the Methods, Results, and Discussion. Acknowledgments and further disclosures (i.e., conflict of interest, data availability statement and, if applicable ethics statement, disclaimer, funding, etc.), References, Figure legends, and Tables follow the body of the text. Systematic Review should also include a brief description (maximum 100 words) of the “Key Summary” of the work on the title page of the paper. These articles must follow PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) reporting guidelines. Per PRISMA guidelines, systematic reviews and meta-analyses must be identified as such in the article title. Tables summarizing literature used in the systematic review should be included as Supplemental material.

Special Articles (including Methods, Hypothesis, and Lecture)

This is limited to invitation only on a recent or emerging topic of public health importance. The text is limited to 3500 words, with up to 50 references and no more than 5 tables and/or figures. An unstructured abstract with 250 words are required. Special Articles should also include a brief description (maximum 75 words) of the “Key Summary” of the work on the title page of the paper. Authors seeking to submit articles on a special topic should first contact the editor.

Brief Reports

Preliminary or novel findings may be reported (limited to 2000 words in the main text, a structured abstract with less than 200 words, a maximum of 3 tables and figures, and up to 20 references). The main text of the brief report must follow the standard JPMPH original article format, with an Introduction and separate sections for the Methods, Results, and Discussion. Case reports can be submitted as Brief Reports category. In the case of case report, informed consent should be obtained from the patients.

Perspectives (including Statistics, Critical Commentary)

Perspectives present a forum for raising awareness to timely public health issues. It provides an opportunity for authors to offer their critical evaluation of recent trends and advances in preventive medicine and public health. Perspectives are limited to 1200 words in the main text, an unstructured abstract with maximum of 200 words, a maximum of 1 table or figure, and up to 10 references. There is no special format of the main text.

Letters to the Editor and Responses

Letters to the Editor offer timely and succinct opinions or interpretations of articles previously published in JPMPH. Letters to the Editor are encouraged up to 6 months after the article is published in JPMPH. The title should be “Comments on <title of the original paper>” and Replies to Letters should be entitled “Reply to: Comments on <title of the original paper>. No abstract is required.
quired. The editors reserve the right to edit and abridge letters and to publish responses. Length should not exceed 1000 words plus 1 figure or table and a maximum of 5 references.

Editorials
Editorials in the *JPMPH* are considered opinion pieces and do not undergo peer review. They may be commissioned by members of the formal editorial team or on occasion, reformatted as editorials from other submitted papers. Editorials are 1000 words in length with no abstract and up to 10 references. Subheadings may be used to guide readers through the major arguments in the text. Authors may upload suggested images as supplemental files at submission. Editor-in-Chief triages editorials to the member of the formal editorial team who is expert in the content area of the column.

Public Health Debates
From time to time *JPMPH* will publish Public Health Debates that will serve as a forum for discussing controversies and critical issues in public health. Typically, 2 articles address a controversial topic and present different or opposing viewpoints. Each author is allowed 1000 words of text and up to 10 references in which to state her or his position. The Editorial member will commission the articles for debate, but authors are welcome to suggest potential topics of interest and to inquire about possible submission. Authors seeking to submit articles on a public health debates should first contact the editor.

Other Publication Types
Other publication types may be accepted. Recommended format can be discussed with Editorial Board.

Manuscript Preparation and Submission Requirements
All manuscripts should be submitted at the *JPMPH* e-submission website (http://submit.jpmph.org). Manuscripts can be submitted at any time. Original source files (cover letter, main text, tables, and figures) are required for submission.

Manuscript Preparation
Manuscripts submitted to the *JPMPH* should be in proper and clear English. Manuscripts should be written and numbered in the following sequence: title page, abstract, keywords, manuscript body, acknowledgements, conflict of interest, data availability statement, ethics statement, and funding, references, tables, and figures.
connect the names by "and." For citations of three or more authors, include the first author’s last name followed by 'et al.' When reporting drug names, generic names should be used. Commercial drug names can be used only when it is important for the study purpose. All measurement numbers should be written in Arabic numbers. When reporting probability, a lowercase $p$ should be used. Percent should be written as % throughout. Lengths are expressed according to the metric system. Temperature is expressed in degrees Celsius, blood pressure as mmHg, and hemoglobin as g/dL. All other measures should be reported in International System of Units (SI Units). A space is placed between a measured value and its unit.

**Supplementary Materials**

If there are any supplementary materials to help the understanding of readers or too great amount data to be included in the main text, it may be placed as supplementary data. They should be cited as Supplemental Material 1, 2,…, etc. They should be numbered in the manuscript by the numerical order in which it is cited. Supplemental material(s) will be published as submitted without editing.

**Conflict of Interest**

It should be disclosed here according to the statement in the Research and Publication Ethics regardless of existence of conflict of interest. If the authors have nothing to disclose, please state: “The authors have no conflicts of interest associated with the material presented in this paper.”

**Funding**

All sources of funding applicable to the study should be stated here explicitly.

**Acknowledgements**

If necessary, persons who have made substantial contributions, but who have not met the criteria for authorship, are acknowledged here.

**Author Contributions**

JPMPH participates in the CRediT standard for author contributions. The contributions of all authors must be described using the CRediT Taxonomy of author roles. For each of the categories below, please enter the initials of the authors who contributed in that category. If no one contributed in a category, you may leave that box blank.

The corresponding author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

Examples of authors’ contributions are as followings:


**ORCID (Open Researcher and Contributor ID)**

ORCID of all authors are recommended to be provided. To have ORCID, authors should register in the ORCID website available from: http://orcid.org/. Registration is free to every researchers in the world.

**References**

Authors are responsible for the accuracy and completeness of references used in the manuscript. All references should be written in English. References written in other languages are indicated by writing (Korean, Japanese, Chinese, etc.) at the end. References should be numbered sequentially and cited in their order of use in the main body of the manuscript. References should be cited according to the system in the Index Medicus used by the U.S. National Library of Medicine as shown in the following examples. Other types of references not described below should follow The NLM Style Guide for Authors, Editors, and Publishers (http://www.nlm.nih.gov/citingmedicine). Avoid using “abstracts,” “unpublished observations” and “personal communications” as references. If an article has been published online, but has not yet been given an issue or pages, the DOI should be supplied.

**Article within a journal**

For six or fewer authors, list the surnames and initials of all authors; for seven or more list the first six authors and add et al., title of article, name of journal abbreviated according to Index Medicus style, year, volume, issue, first and last page numbers.


Books

Chapter in books

Data found on the Internet

Preprint

Theses

Tables and Figures
The use of tables, figures, and photographs that supplement the text are recommended but should not duplicate material found in the body of the manuscript. Tables and figures are placed at the end of the manuscript body and should be numbered (Arabic numerals) in the sequence in which they appear in the text. Approximate locations should be marked in the manuscript body. Titles for tables and figures should be self-explanatory with the first word written with an upper case letter and the rest in lower case letters. The same principle is applied to the content of a table or figure. Tables are prepared with no horizontal or vertical dividing lines. Explanations for and abbreviations used in tables and figures are included as footnotes. Footnotes are indicated by superscript numbers in numerical order (1,2,3…). A p-value may be indicated as follows in the footnotes: 1p<0.1, *p<0.05, **p<0.01, ***p<0.001, etc.

Korean Summary
The Korean Summary in Korean is requested only for Korean authors and for original articles, review articles, special articles, and brief reports in this issue. The files of published articles are supplied through an icon “Korean Summary” in the electronic table of contents on the website of JPMPH (https://www.jpmph.org/). If the authors want to publish full Korean version of the manuscript, please contact editorial board.

Graphic Abstract
A graphical abstract is required for original articles, review articles, special articles, and brief communications. The graphical abstract should clearly represent the topic of the article in a pictorial form designed to capture the attention of a wide readership. Authors must provide one image according to the guidelines in the section of Tables and Figures.

Review Process
Upon submission of a manuscript, the board of editors for the JPMPH will review the paper for appropriateness of content. Articles can be rejected at this initial review process. Articles that pass this preview are then reviewed by two or three experts in the field selected by the board of editors. When a member of the board of editors submits a paper, the member is excluded from the review of the paper and the anonymity, fairness and security of the appointment of reviewers are strictly maintained. The authors’ names and affiliations are removed during peer review. In addition, review comments and opinions are not disclosed to anyone other than the authors and the board of editors during the entire review process. Double-blind peer review averages 2 months to complete. The board of editors reserves the right to edit a manuscript for phrasing, style, and overall length at any stage prior to publication, while maintaining the scientific accuracy of the manuscript. Based on comments from reviewers and editors, authors may be asked to revise their manuscript. Authors are required to submit a letter of explanation regarding how they dealt with all comments and questions raised by reviewers and editors. If revisions cannot be submitted within one month, author(s) may request a one-month grace period. If the revised manuscript is not submitted within the required period, the manuscript will automatically be rejected. Manuscripts will not be returned after submission.

Appeal of the Result for Review Process
If the authors do not comply with the review result, the authors may raise an objection by submitting the reason to the board of editors by e-mail within 7 days of notification of the review result. When an objection is raised, the Editor-in-Chief con-
venes a temporary editorial committee and considers it as an official agenda. After the board of editors comprehensively reviews the original text, review opinions, and content of objections, the editorial committee notifies the authors of the review result within 7 days.

**After Acceptance**

**Production Process**
After acceptance, all submissions are transferred to *JPMPH* production team for handling. The corresponding author will receive an email from the production team outlining the steps required to move the manuscript through to publication. All accepted manuscripts are subject to copy editing by the editorial office to achieve consistency of style and formatting of journal content.

**Conflict of Interest Statement for Papers Accepted for Publication**
To maintain a transparent process throughout the writing and publishing of a scientific article, when a paper has been accepted for publication, each author will be required to sign a formal conflict of interest statement, which includes author contribution information. Each author will have to certify that he/she meets ALL four criteria of authorship as recommended by the ICMJE (http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html).

**Copyright**
Copyright of all material is held by the Korean Society for Preventive Medicine. Authors may use their own material in other publications provided that *JPMPH* is acknowledged as the original place of publication.

**Preprint Policy**
*JPMPH* do not allows a paper that has not conducted peer review on a preprint server such as the MedRxiv, Research square, and bioRxiv.

**Embargo**
All material accepted for publication in *JPMPH* is under embargo until it is published online. This means that until then it shouldn’t be distributed to third parties or discussed with the media.

**Postprint Publication**
The post publication version of the manuscript can be used after discussing editorial office.

**Contact Us**
Any inquiry including submissions, the review process, certification of acceptance, or copyrights should be directed to the editor from the website (https://www.jpmph.org/about/contact.php) or sent via surface mail or fax to:

**Editor-in-Chief:** Sung-il Cho  
Graduate School of Public Health, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea  
Tel: +82-2-880-2717, Fax: +82-2-764-8328  
E-mail: editor.jpmph@gmail.com

**Editorial Office:** Korean Society for Preventive Medicine  
#203, 92 Wangsan-ro, Dongdaemun-gu, Seoul 02585, Korea  
Tel: +82-2-740-8328, Fax: +82-2-764-8328  
E-mail: jpmph@prevmed.or.kr

**NOTICE:** These instructions to authors will be applied beginning with the September 2023 issue.